Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
MEIP | US
0.10
3.29%
Healthcare
Drug Manufacturers-Specialty & Generic
31/03/2024
19/09/2024
3.14
3.15
3.21
3.06
MEI Pharma Inc. a late-stage pharmaceutical company focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib an oral cyclin-dependent kinase 9 inhibitor which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344 a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat an oral available histone deacetylase inhibitor which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma Inc. has a license development and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene Ltd.; a license development manufacturing and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences Inc. The company was formerly known as Marshall Edwards Inc. and changed its name to MEI Pharma Inc. in July 2012. MEI Pharma Inc. was incorporated in 2000 and is headquartered in San Diego California.
View LessStrength based on increasing price with high volume
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Operating Margin (> 25%)
Strong Revenue Growth (> 10%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
44.1%1 month
42.6%3 months
63.5%6 months
55.3%0.77
-
0.40
0.23
0.16
-1.58
1.39
20.60
20.73M
20.92M
20.92M
-
30.53
-
648.00
61.27
0.55
0.20
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.31
Range1M
0.40
Range3M
1.32
Rel. volume
1.31
Price X volume
60.01K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Flora Growth Corp. Common Stock | FLGC | Drug Manufacturers-Specialty & Generic | 1.42 | 18.98M | 35.24% | n/a | 76.81% |
Cumberland Pharmaceuticals Inc | CPIX | Drug Manufacturers-Specialty & Generic | 1.28 | 18.04M | 2.40% | n/a | 81.86% |
Guardion Health Sciences Inc | GHSI | Drug Manufacturers-Specialty & Generic | 10.85 | 13.93M | 3.63% | n/a | 0.00% |
BGXX | BGXX | Drug Manufacturers-Specialty & Generic | 0.06 | 11.47M | -59.49% | n/a | 5.20% |
Universe Pharmaceuticals INC | UPC | Drug Manufacturers-Specialty & Generic | 0.3412 | 8.07M | -4.16% | n/a | 13.87% |
Biofrontera Inc. Common Stock | BFRI | Drug Manufacturers-Specialty & Generic | 1.28 | 7.10M | -0.78% | n/a | 13.20% |
Imc Mortgage Co | IMCC | Drug Manufacturers-Specialty & Generic | 2.15 | 4.80M | -4.02% | n/a | 222.75% |
Sonoma Pharmaceuticals Inc | SNOA | Drug Manufacturers-Specialty & Generic | 3.83 | 3.93M | -10.93% | n/a | 8.44% |
Avenue Therapeutics Inc | ATXI | Drug Manufacturers-Specialty & Generic | 2.61 | 3.74M | -3.33% | 0.07 | 0.00% |
Evoke Pharma Inc | EVOK | Drug Manufacturers-Specialty & Generic | 4.44 | 3.64M | 4.72% | 0.04 | 187.62% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ILAG | ILAG | Building Products & Equipment | 1.04 | 18.78M | 13.06% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 1.02 | 12.43M | -7.27% | n/a | 16.03% |
The Dixie Group Inc | DXYN | Textile Manufacturing | 0.737 | 11.34M | 3.80% | n/a | 422.08% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.6475 | 6.16M | -2.76% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.315 | 4.97M | -1.56% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.42 | 3.63M | 1.43% | n/a | 9.62% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 0.751 | 1.10M | 24.54% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 915.21K | -8.33% | n/a | -37.05% |
Blackstone/GSO Senior Floating Rate Term Fund | BSL | Textile Manufacturing | 14.31 | 0 | 0.35% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.58 | 16.67 | Cheaper |
Ent. to Revenue | 1.39 | 309.37 | Cheaper |
PE Ratio | 0.77 | 29.14 | Cheaper |
Price to Book | 0.40 | 12.81 | Cheaper |
Dividend Yield | - | 2.80 | - |
Std. Deviation (3M) | 63.50 | 75.12 | Par |
Debt to Equity | 0.23 | -0.93 | Expensive |
Debt to Assets | 0.16 | 0.45 | Cheaper |
Market Cap | 20.92M | 5.22B | Emerging |